Antisense Therapeutics Limited announce the appointment of Charmaine Gittleson M.D as a Non-Executive Director of the Company. Dr. Gittleson is a senior executive with extensive international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company CSL Limited. At CSL Dr. Gittleson held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States. Dr. Gittleson's appointment is effective immediately and will be confirmed with shareholders following the 2021 Annual General Meeting at which time Dr. Graham Mitchell, current non-executive director of ANP intends to retire from the Board of Directors and so will not seek re-election.